FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3170210367> ?p ?o ?g. }

• W3170210367 endingPage "11515" @default.
• W3170210367 startingPage "11515" @default.
• W3170210367 abstract "11515 Background: Dedifferentiated liposarcoma (DDL) is characterized by ring chromosomes of chromosone12, which includes amplification of MDM2 and CDK4. Exposure to CDK4 inhibitors in Rb+ leiomyosarcoma (LMS) cell lines leads to decreased cell proliferation, and increased senescence, and G0/G1-phase arrest. When combined, ribociclib a CDK4 inhibitor and everolimus, an mTOR inhibitor show synergistic growth inhibition in multiple tumor models. We hypothesized that this combination could lead to increased disease control in patients with DDL. Methods: This study enrolled patients (pts) into one of two cohorts: DDL or Rb+ LMS. LMS pts were required to have 1 prior line of therapy; DDL pts required no prior therapy. There were no limits to prior therapies in either group. Measurable disease by RECIST 1.1 was also required. Ribociclib was given at 300 mg daily for 21/28 days and everolimus was given continuously at 2.5 mg daily in 28 day cycles. The primary endpoint was progression free rate at 16 weeks. A Simon two-stage design was utilized and if at least 8 out of 24 pts were progression free at 16 weeks, the treatment was declared promising for the cohort. Here in we present data on the DDL cohort. Results: To date, 21 DDS pts, median age of 63 (range 40-79), of which 43% (n = 9) female were treated. Median prior lines of therapy was 1 (range 0-6). Of 19 pts with complete data, 8 (42%) met the primary endpoint of non-progression at 16 weeks. Confirmed partial response was seen in 2 pts (10%). Median PFS was 16 weeks, and stable disease occurring as best response in 11 (55%) pts. Grade 3-4 toxicities were uncommon except for lymphopenia (24%) and neutropenia (33%); no episode of neutropenic fever were observed. There was one death on study secondary to myocardial infarction, considered possibly related to therapy. Results of optional tissue biopsies pre and on therapy obtained to assess pharmacodynamic changes in PTEN, pAKT, CDK4, Rb and pS6 will be presented. Conclusions: The combination of ribociclib and everolimus demonstrates activity in DDL with prolonged stable disease (>16 weeks) meeting the primary protocol endpoint. Notably partial responses were also observed. The combination was well tolerated with acceptable side effects. Updated outcomes will be presented. Clinical trial information: NCT03114527." @default.
• W3170210367 created "2021-06-22" @default.
• W3170210367 creator A5011532185 @default.
• W3170210367 creator A5012283707 @default.
• W3170210367 creator A5016691697 @default.
• W3170210367 creator A5025874222 @default.
• W3170210367 creator A5042802176 @default.
• W3170210367 creator A5064214267 @default.
• W3170210367 creator A5070223037 @default.
• W3170210367 creator A5071532449 @default.
• W3170210367 creator A5071911718 @default.
• W3170210367 creator A5075315687 @default.
• W3170210367 creator A5078289621 @default.
• W3170210367 creator A5078325539 @default.
• W3170210367 creator A5085336500 @default.
• W3170210367 creator A5091383750 @default.
• W3170210367 date "2021-05-20" @default.
• W3170210367 modified "2023-09-23" @default.
• W3170210367 title "Outcomes in the dedifferentiated liposarcoma cohort of SAR-096, a phase II trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS)." @default.
• W3170210367 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.11515" @default.
• W3170210367 hasPublicationYear "2021" @default.
• W3170210367 type Work @default.
• W3170210367 sameAs 3170210367 @default.
• W3170210367 citedByCount "0" @default.
• W3170210367 crossrefType "journal-article" @default.
• W3170210367 hasAuthorship W3170210367A5011532185 @default.
• W3170210367 hasAuthorship W3170210367A5012283707 @default.
• W3170210367 hasAuthorship W3170210367A5016691697 @default.
• W3170210367 hasAuthorship W3170210367A5025874222 @default.
• W3170210367 hasAuthorship W3170210367A5042802176 @default.
• W3170210367 hasAuthorship W3170210367A5064214267 @default.
• W3170210367 hasAuthorship W3170210367A5070223037 @default.
• W3170210367 hasAuthorship W3170210367A5071532449 @default.
• W3170210367 hasAuthorship W3170210367A5071911718 @default.
• W3170210367 hasAuthorship W3170210367A5075315687 @default.
• W3170210367 hasAuthorship W3170210367A5078289621 @default.
• W3170210367 hasAuthorship W3170210367A5078325539 @default.
• W3170210367 hasAuthorship W3170210367A5085336500 @default.
• W3170210367 hasAuthorship W3170210367A5091383750 @default.
• W3170210367 hasConcept C126322002 @default.
• W3170210367 hasConcept C126894567 @default.
• W3170210367 hasConcept C141071460 @default.
• W3170210367 hasConcept C142724271 @default.
• W3170210367 hasConcept C143998085 @default.
• W3170210367 hasConcept C203092338 @default.
• W3170210367 hasConcept C2776694085 @default.
• W3170210367 hasConcept C2777532014 @default.
• W3170210367 hasConcept C2778256501 @default.
• W3170210367 hasConcept C2778822529 @default.
• W3170210367 hasConcept C2779568860 @default.
• W3170210367 hasConcept C2779699572 @default.
• W3170210367 hasConcept C535046627 @default.
• W3170210367 hasConcept C71924100 @default.
• W3170210367 hasConcept C72563966 @default.
• W3170210367 hasConceptScore W3170210367C126322002 @default.
• W3170210367 hasConceptScore W3170210367C126894567 @default.
• W3170210367 hasConceptScore W3170210367C141071460 @default.
• W3170210367 hasConceptScore W3170210367C142724271 @default.
• W3170210367 hasConceptScore W3170210367C143998085 @default.
• W3170210367 hasConceptScore W3170210367C203092338 @default.
• W3170210367 hasConceptScore W3170210367C2776694085 @default.
• W3170210367 hasConceptScore W3170210367C2777532014 @default.
• W3170210367 hasConceptScore W3170210367C2778256501 @default.
• W3170210367 hasConceptScore W3170210367C2778822529 @default.
• W3170210367 hasConceptScore W3170210367C2779568860 @default.
• W3170210367 hasConceptScore W3170210367C2779699572 @default.
• W3170210367 hasConceptScore W3170210367C535046627 @default.
• W3170210367 hasConceptScore W3170210367C71924100 @default.
• W3170210367 hasConceptScore W3170210367C72563966 @default.
• W3170210367 hasFunder F4320307778 @default.
• W3170210367 hasFunder F4320332523 @default.
• W3170210367 hasIssue "15_suppl" @default.
• W3170210367 hasLocation W31702103671 @default.
• W3170210367 hasOpenAccess W3170210367 @default.
• W3170210367 hasPrimaryLocation W31702103671 @default.
• W3170210367 hasRelatedWork W1884818927 @default.
• W3170210367 hasRelatedWork W2008503184 @default.
• W3170210367 hasRelatedWork W2026146942 @default.
• W3170210367 hasRelatedWork W2128810106 @default.
• W3170210367 hasRelatedWork W2279293741 @default.
• W3170210367 hasRelatedWork W2318279699 @default.
• W3170210367 hasRelatedWork W2921652393 @default.
• W3170210367 hasRelatedWork W3035937788 @default.
• W3170210367 hasRelatedWork W3170210367 @default.
• W3170210367 hasRelatedWork W4281753967 @default.
• W3170210367 hasVolume "39" @default.
• W3170210367 isParatext "false" @default.
• W3170210367 isRetracted "false" @default.
• W3170210367 magId "3170210367" @default.
• W3170210367 workType "article" @default.